Â鶹ѧÉú¾«Æ·°æ

Journal Article

1. Levic DS, Niedzwiecki D, Kandakatla A, Karlovich NS, Juneja A, Park J, Stolarchuk C, Adams S, Willer JR, Schaner MR, Lian G, Beasley C, Marjoram L, Flynn AD, Valentine JF, Onken JE, Sheikh SZ, Davis EE, Evason KJ, Garman KS, Bagnat M (). TNF promoter hypomethylation is associated with mucosal inflammation in IBD and anti-TNF response. medRxiv (Preprint)  2024 Feb 6:2024. (Epub ahead of print) medRxiv.
2. Chulkina M, Rohmer C, McAninch S, Panganiban RP, Villger R, Portolese A, Ciocirlan J, Yang W, Cohen C, Koltun W, Valentine JF, Cong Y, Yochum G, Beswick EJ, Pinchuk IV (2023). Increased Activity of MAPKAPK2 within Mesenchymal Cells as a Target for Inflammation-Associated Fibrosis in Crohn's Disease. J Crohns Colitis, 18(7), 1147-1161. ()
3. Lee YJ, Li D, Mujukian A, Debbas P, Hampton M, Mengesha E, Cheng S, Ebinger JE, Chiorean M, Lum D, Damas OM, Braun J, McGovern DPB, Melmed GY, CORALE-IBD Study Group (2023). Postvaccination Symptoms After a Fourth Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis, 30(8), 1430-1434. ()
4. Colombel JF, Ungaro RC, Sands BE, Siegel CA, Wolf DC, Valentine JF, Feagan BG, Neustifter B, Kadali H, Nazarey P, James A, Jairath V, Qasim Khan RM (2023). Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER). Clin Gastroenterol Hepatol, 22(7), 1487-1496.e12. ()
5. Levic DS, Niedzwiecki D, Kandakatla A, Karlovich NS, Juneja A, Park J, Stolarchuk C, Adams S, Willer JR, Schaner MR, Lian G, Beasley C, Marjoram L, Flynn AD, Valentine JF, Onken JE, Sheikh SZ, Davis EE, Evason KJ, Garman KS, Bagnat M (2024). TNF Promoter Hypomethylation Is Associated With Mucosal Inflammation in IBD and Anti-TNF Response. Gastro Hep Adv, 3(7), 888-898. ()
6. Lewis JD, Daniel SG, Li H, Hao F, Patterson AD, Hecht A, Brensinger CM, Wu GD, Bittinger K, DINE-CD and SPARC IBD Investigators, Kaur M, Dassopoulos T, Snapper SB, Korzenik JR, Bohm M, Raffals L, Beniwal-Patel P, Hudesman D, Russ K, Brook L, Pekow J, Cross R, Wong U, Bishu S, Bewtra M, Lewis JD, Duerr R, Saha S, Caldera F, Scoville E, Deepak P, Ciorba M (2024). Surgery for Crohn's Disease Is Associated with a Dysbiotic Microbiome and Metabolome: Results from Two Prospective Cohorts. Cell Mol Gastroenterol Hepatol, 18(3), 101357. ()
7. Levic DS, Niedzwiecki D, Kandakatla A, Karlovich NS, Juneja A, Park J, Stolarchuk C, Adams S, Willer JR, Schaner MR, Lian G, Beasley C, Marjoram L, Flynn AD, Valentine JF, Onken JE, Sheikh SZ, Davis EE, Evason KJ, Garman KS, Bagnat M (2024). TNF promoter hypomethylation is associated with mucosal inflammation in IBD and anti-TNF response. ()
8. Chulkina M, Rohmer C, McAninch S, Panganiban RP, Villger R, Portolese A, Ciocirlan J, Yang W, Cohen C, Koltun W, Valentine JF, Cong Y, Yochum G, Beswick EJ, Pinchuk IV (2024). Increased activity of MAPKAPK2 within mesenchymal cells as a target for inflammation associated fibrosis in Crohn's Disease. J Crohns Colitis, 18(7), 1147-1161. ()
9. Lewis JD, Daniel SG, Li H, Hao F, Patterson AD, Hecht AL, Brensinger CM, Wu GD, Bittinger K, DINE-CD, SPARC IBD Investigators (2024). Surgery for Crohn's Disease Is Associated With a Dysbiotic Microbiome and Metabolome: Results From Two Prospective Cohorts. Cell Mol Gastroenterol Hepatol, 18(3), 101357. ()
10. Colombel JF, Ungaro RC, Sands BE, Siegel CA, Wolf DC, Valentine JF, Feagan BG, Neustifter B, Kadali H, Nazarey P, James A, Jairath V, Qasim Khan RM (2023). Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER). Clin Gastroenterol Hepatol, 22(7), 1487-1496.e12. ()
11. Toy G, Colletier K, Hale G, Valentine J, Gawron AJ, Sossenheimer M, Peterson K, Aparicio R, Fang JC (2023). Incidence of retained biopsy specimens after esophagogastroduodenoscopy and colonoscopy. Endosc Int Open, 11(7), E653-E659. ()
12. Mohan BP, Fatima N, Khan SR, Kassab L, Chandan S, Asokkumar R, Valentine JF, Navaneethan U, Kochhar GS, Ma C, Jairath V, Singh S (2023). Early Remission With Induction Therapy Predicts Long-Term Remission in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.   PMID: 37207296 DOI: 10.14309/ajg.0000000000002328 . Am J Gastroenterol. ()
13. Lebish EJ, Morgan NJ, Valentine JF, Beswick EJ (2022). MK2 Inhibitors as a Potential Crohn's Disease Treatment Approach for Regulating MMP Expression, Cleavage of Checkpoint Molecules and T Cell Activity. Pharmaceuticals (Basel), 15(12). ()
14. Tsai HY, Bronner MP, March JK, Valentine JF, Shroyer NF, Lai LA, Brentnall TA, Pan S, Chen R (2022). Metabolic targeting of NRF2 potentiates the efficacy of the TRAP1 inhibitor G-TPP through reduction of ROS detoxification in colorectal cancer. Cancer Lett, 549, 215915. ()
15. Sandborn WJ, Pans J, Danese S, Sharafali Z, Hassanali A, Jacob-Moffatt R, Eden C, Daperno M, Valentine JF, Laharie D, Baa C, Atreya R, Panaccione R, Rydzewska G, Aguilar H, Vermeire S, BERGAMOT Study Group (2022). Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. ()
16. Papamichael K, Jairath V, Zou G, Cohen B, Ritter T, Sands B, Siegel C, Valentine J, Smith M, Vande Casteele N, Dubinsky M, Cheifetz A (2022). Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial). BMJ Open, 12(4), e057656. ()
17. Tse CS, Van Citters AD, Ricci B, Freundlich NZ, Lee M, Shah SA, Melmed GY, Siegel CA, van Deen WK, IBD Qorus (2021). Identifying and Predicting the Goals and Concerns Prioritised by Individuals with Inflammatory Bowel Disease. J Crohns Colitis, 16(3), 379-388. ()
18. Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV Jr, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ, HICKORY Study Group (2021). Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol Hepatol, 7(2), 128-140. ()
19. Rubin DT, Dotan I, DuVall A, Bouhnik Y, Radford-Smith G, Higgins PDR, Mishkin DS, Arrisi P, Scalori A, Oh YS, Tole S, Chai A, Chamberlain-James K, Lacey S, McBride J, Pans J, HIBISCUS Study Group (2021). Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. Lancet Gastroenterol Hepatol, 7(1), 17-27. ()
20. Vermeire S, Lakatos PL, Ritter T, Hanauer S, Bressler B, Khanna R, Isaacs K, Shah S, Kadva A, Tyrrell H, Oh YS, Tole S, Chai A, Pulley J, Eden C, Zhang W, Feagan BG, LAUREL Study Group (2021). Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Lancet Gastroenterol Hepatol, 7(1), 28-37. ()
21. Ost KS, OMeara TR, Stephens WZ, Chiaro T, Zhou H, Penman J, Bell R, Catanzaro JR, Song D, Singh S, Call DH, Hwang-Wong E, Hanson KE, Valentine JF, Christensen KA, OConnell RM, Cormack B, Ibrahim AS, Palm NW, Noble SM, Round JL (2021). Adaptive immunity induces mutualism between commensal eukaryotes. Nature, 596(7870), 114-118. ()
22. Lewis JD, Sandler R, Brotherton C, Brensinger C, Li H, Kappelman MD, Daniel SG, Bittinger K, Albenberg L, Valentine JF, Hanson J, Suskind D, Meyer A, Compher CW, Bewtra M, Saxena A, Dobes A, Cohen B, Flynn AD, Fischer M, Saha S, Swaminath A, Yacyshyn B, Scherl E, Horst S, Curtis JR, Braly K, Nessel L, McCauley M, McKeever L, Herfarth H, DINE-CD Study Group (2021). A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults with Crohn's Disease. Gastroenterology, 161, 837-852.e9. ()
23. Somineni HK, Nagpal S, Venkateswaran S, Cutler DJ, Okou DT, Haritunians T, Simpson CL, Begum F, Datta LW, Quiros AJ, Seminerio J, Mengesha E, Alexander JS, Baldassano RN, Dudley-Brown S, Cross RK, Dassopoulos T, Denson LA, Dhere TA, Iskandar H, Dryden GW, Hou JK, Hussain SZ, Hyams JS, Isaacs KL, Kader H, Kappelman MD, Katz J, Kellermayer R, Kuemmerle JF, Lazarev M, Li E, Mannon P, Moulton DE, Newberry RD, Patel AS, Pekow J, Saeed SA, Valentine JF, Wang MH, McCauley JL, Abreu MT, Jester T, Molle-Rios Z, Palle S, Scherl EJ, Kwon J, Rioux JD, Duerr RH, Silverberg MS, Zwick ME, Stevens C, Daly MJ, Cho JH, Gibson G, McGovern DPB, Brant SR, Kugathasan S (2021). Whole-genome sequencing of African Americans implicates differential genetic architecture in inflammatory bowel disease. Am J Hum Genet, 108(3), 431-445. ()
24. Samadder NJ, Valentine JF, Guthery S, Singh H, Bernstein CN, Leighton JA, Wan Y, Wong J, Boucher K, Pappas L, Rowe K, Burt RW, Curtin K, Smith KR (2018). Family History Associates With Increased Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol, 17(9), 1807-1813.e1. ()
25. Gogokhia L, Buhrke K, Bell R, Hoffman B, Brown DG, Hanke-Gogokhia C, Ajami NJ, Wong MC, Ghazaryan A, Valentine JF, Porter N, Martens E, OConnell R, Jacob V, Scherl E, Crawford C, Stephens WZ, Casjens SR, Longman RS, Round JL (2018). Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis. Cell Host Microbe, 25(2), 285-299.e8. ()
26. Herfarth H, Barnes EL, Valentine JF, Hanson J, Higgins PDR, Isaacs KL, Jackson S, Osterman MT, Anton K, Ivanova A, Long MD, Martin C, Sandler RS, Abraham B, Cross RK, Dryden G, Fischer M, Harlan W, Levy C, McCabe R, Polyak S, Saha S, Williams E, Yajnik V, Serrano J, Sands BE, Lewis JD, Clinical Research Alliance of the Crohns and Colitis Foundation (2018). Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis. Gastroenterology, 155(4), 1098-1108.e9. ()
27. Johnson J, Affolter K, Boynton K, Chen X, Valentine J, Peterson K (2017). CMV Disease in IBD: Comparison of Diagnostic Tests and Correlation with Disease Outcome. Inflamm Bowel Dis, 24(7), 1539-1546. ()
28. Brant SR, Okou DT, Simpson CL, Cutler DJ, Haritunians T, Bradfield JP, Chopra P, Prince J, Begum F, Kumar A, Huang C, Venkateswaran S, Datta LW, Wei Z, Thomas K, Herrinton LJ, Klapproth JA, Quiros AJ, Seminerio J, Liu Z, Alexander JS, Baldassano RN, Dudley-Brown S, Cross RK, Dassopoulos T, Denson LA, Dhere TA, Dryden GW, Hanson JS, Hou JK, Hussain SZ, Hyams JS, Isaacs KL, Kader H, Kappelman MD, Katz J, Kellermayer R, Kirschner BS, Kuemmerle JF, Kwon JH, Lazarev M, Li E, Mack D, Mannon P, Moulton DE, Newberry RD, Osuntokun BO, Patel AS, Saeed SA, Targan SR, Valentine JF, Wang MH, Zonca M, Rioux JD, Duerr RH, Silverberg MS, Cho JH, Hakonarson H, Zwick ME, McGovern DP, Kugathasan S (2017). Genome-Wide Association Study Identifies African-Specific Susceptibility Loci in African Americans With Inflammatory Bowel Disease. Gastroenterology, 152(1), 206-217.e2. ()
29. Huang C, Haritunians T, Okou DT, Cutler DJ, Zwick ME, Taylor KD, Datta LW, Maranville JC, Liu Z, Ellis S, Chopra P, Alexander JS, Baldassano RN, Cross RK, Dassopoulos T, Dhere TA, Duerr RH, Hanson JS, Hou JK, Hussain SZ, Isaacs KL, Kachelries KE, Kader H, Kappelman MD, Katz J, Kellermayer R, Kirschner BS, Kuemmerle JF, Kumar A, Kwon JH, Lazarev M, Mannon P, Moulton DE, Osuntokun BO, Patel A, Rioux JD, Rotter JI, Saeed S, Scherl EJ, Silverberg MS, Silverman A, Targan SR, Valentine JF, Wang MH, Simpson CL, Bridges SL, Kimberly RP, Rich SS, Cho JH, Rienzo AD, Kao LWH, McGovern DPB, Brant SR, Kugathasan S (2015). Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans. Gastroenterology, 149(6), 1575-1586. ()
30. Runtsch MC, Hu R, Alexander M, Wallace J, Kagele D, Petersen C, Valentine JF, Welker NC, Bronner MP, Chen X, Smith DP, Ajami NJ, Petrosino JF, Round JL, OConnell RM (2015). MicroRNA-146a constrains multiple parameters of intestinal immunity and increases susceptibility to DSS colitis. Oncotarget, 6(30), 28556-72. ()
31. Melmed GY, Pandak WM, Casey K, Abraham B, Valentine J, Schwartz D, Awais D, Bassan I, Lichtiger S, Sands B, Hanauer S, Richards R, Oikonomou I, Parekh N, Targan S, Johnson K, Hariri R, Fischkoff S (2015). Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe Crohn's Disease: A Phase 1b/2a Study. Inflamm Bowel Dis, 21(8), 1809-16. ()
32. Koboziev I, Jones-Hall Y, Valentine JF, Webb CR, Furr KL, Grisham MB (2015). Use of Humanized Mice to Study the Pathogenesis of Autoimmune and Inflammatory Diseases. Inflamm Bowel Dis, 21(7), 1652-73. ()
33. Panaccione R, Sandborn WJ, Gordon GL, Lee SD, Safdi A, Sedghi S, Feagan BG, Hanauer S, Reinisch W, Valentine JF, Huang B, Carcereri R (2015). Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis, 21(6), 1329-40. ()
34. Xia CQ, Peng R, Chernatynskaya AV, Yuan L, Carter C, Valentine J, Sobel E, Atkinson MA, Clare-Salzler MJ (2014). Increased IFN-α-producing plasmacytoid dendritic cells (pDCs) in human Th1-mediated type 1 diabetes: pDCs augment Th1 responses through IFN-α production. J Immunol, 193(3), 1024-34.
35. Faubion WA Jr, Fletcher JG, OByrne S, Feagan BG, de Villiers WJ, Salzberg B, Plevy S, Proctor DD, Valentine JF, Higgins PD, Harris JM, Diehl L, Wright L, Tew GW, Luca D, Basu K, Keir ME (2013). EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging. Am J Gastroenterol, 108(12), 1891-900. ()
36. Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, Ullman T, Glover S, Valentine JF, Rubin DT, Miller J, Abreu MT (2013). Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol, 11(3), 286-92; quiz e24. ()
37. Ukhanova M, Culpepper T, Baer D, Gordon D, Kanahori S, Valentine J, Neu J, Sun Y, Wang X, Mai V (2012). Gut microbiota correlates with energy gain from dietary fiber and appears to be associated with acute and chronic intestinal diseases. Clin Microbiol Infect, 18, 62-66.
38. Wang MH, Okazaki T, Kugathasan S, Cho JH, Isaacs KL, Lewis JD, Smoot DT, Valentine JF, Kader HA, Ford JG, Harris ML, Oliva-Hemker M, Cuffari C, Torbenson MS, Duerr RH, Silverberg MS, Rioux JD, Taylor KD, Nguyen GC, Wu Y, Datta LW, Hooker S, Dassopoulos T, Kittles RA, Kao LW, Brant SR (2012). Contribution of higher risk genes and European admixture to Crohn's disease in African Americans. Inflamm Bowel Dis, 18(12), 2277-87. ()
39. Davis MK, Valentine JF, Weinstein DA, Polyak S (2010). Antibodies to CBir1 are associated with glycogen storage disease type Ib. J Pediatr Gastroenterol Nutr, 51(1), 14-8. ()
40. Ahmadi A, Li Q, Muller K, Collins D, Valentine JF, Drane W, Polyak S (2010). Diagnostic value of noninvasive combined fluorine-18 labeled fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography enterography in active Crohn's disease. Inflamm Bowel Dis, 16(6), 974-81. ()
41. Dassopoulos T, Nguyen GC, Talor MV, Datta LW, Isaacs KL, Lewis JD, Gold MS, Valentine JF, Smoot DT, Harris ML, Oliva-Hemker M, Bayless TM, Burek CL, Brant SR (2010). NOD2 mutations and anti-Saccharomyces cerevisiae antibodies are risk factors for Crohn's disease in African Americans. Am J Gastroenterol, 105(2), 378-86. ()
42. Valentine JF, Fedorak RN, Feagan B, Fredlund P, Schmitt R, Ni P, Humphries TJ (2009). Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study. Gut, 58(10), 1354-62. ()
43. Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ (2005). Sargramostim for active Crohn's disease. N Engl J Med, 352(21), 2193-201. ()
44. Naser SA, Ghobrial G, Romero C, Valentine JF (2004). Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease. Lancet, 364(9439), 1039-44. ()
45. Valentine JF (2001). Mesalamine induces manganese superoxide dismutase in rat intestinal epithelial cell lines and in vivo. Am J Physiol Gastrointest Liver Physiol, 281(4), G1044-50. ()

Abstract

1. Mach A, Glover S, Valentine JF (2012). GM-CSF and IL23 Protect the Intestinal Epithelial Barrier from Disruption by IFN Treatment. [Abstract]. DDW- Sandiego, CA.
2. Gaidos JKJ, Sultan S, Dahl W, Valentine JF (Dec 9-12, 2010). Vitamin D Deficiency in Inflammatory Bowel Disease. Advances in IBD Annual CCFA Meeting. Ft. Lauderdale, FL. [Abstract].

Patent

1. Valentine JF (2004). Manganese superoxide dismutase regulatory elements and the uses thereof. U.S. Patent No. 6,800,458. Washington, D.C.:U.S. Patent and Trademark Office.

Podcasts

• Treatments for Inflammatory Bowel Disease
• Inflammatory Bowel Disease: Symptoms, Diagnosis, and When to See a Specialist